Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: EMG produced TPA metagenomics assembly of the Metagenomic analysis of fecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer (Metagenomic analysis of fecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer) data set.

PROVIDER: PRJEB24748 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1018243.fasta.gz	Fasta.gz
	ERR1018279.fasta.gz	Fasta.gz
	ERR1018204.fasta.gz	Fasta.gz
	ERR1018195.fasta.gz	Fasta.gz
	ERR1018237.fasta.gz	Fasta.gz

Items per page:

1 - 5 of 384

Similar Datasets

Metagenomic analysis of fecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer

Project description:Metagenomic analysis of fecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer

| PRJEB10878 | ENA

Project description:Metagenomic analysis of faecal microbiome as a tool for targeted non-invasive biomarkers for inflammatory bowel disease

| PRJNA1086048 | ENA

First approach on the use of samples from fecal occult blood screening kits for metabolomic analysis. Application in colorectal cancer population.

Project description:Cancer is the most common disease around the world and colorectal cancer is the second most common cancer. The early diagnosis of colorectal cancer is difficult and relies on invasive diag-nostic tools such as colonoscopy and tissue biopsy. Other non-invasive techniques such as fecal occult blood screening test (FOBT) are less sensitive and accurate. The advantage of FOBT together with high throughput technology such as metabolomics could provide the advantages of non-invasive tool and the effectiveness of detecting novel colorectal cancer markers. In this way, this work focuses on the novelty of using FOBT as samples to perform metabolomics analysis and its application on colorectal cancer population.

2022-12-09 | ST002468 | MetabolomicsWorkbench

Risk Stratification of Colorectal Adenomas and Cancer From Stool Microbiota

Project description:using fecal microbiota composition as a non-invasive diagnostic tool to classify colorectal carcinoma and adenoma.

| PRJEB29239 | ENA

Risk Stratification of Colorectal Adenomas and Cancer From Stool Microbiota

Project description:using fecal microbiota composition as a non-invasive diagnostic tool to classify colorectal carcinoma and adenoma.

| PRJEB35850 | ENA

Discovering biomarkers for non-alcoholic steatohepatitis pa-tients with and without hepatocellular carcinoma using fecal metaproteomics

Project description:High-calorie diets lead hepatic steatosis and to the development of non-alcoholic fatty liver disease (NAFLD), which can evolve over many years into the inflammatory form non-alcoholic steatohepatits (NASH) posing a risk for the development of hepatocellular carcinoma (HCC). Due to the diet and the liver alteration, the axis between liver and gut is disturbed, resulting in gut microbiome alterations. Consequently, detecting these gut microbiome alterations repre-sents a promising strategy for early NASH and HCC detection. We analyzed medical parame-ters and the fecal metaproteome of 19 healthy controls, 32 NASH, and 29 HCC patients target-ing the discovery of diagnostic biomarkers. Here, NASH and HCC resulted in increased in-flammation status and shifts within the composition of the gut microbiome. Increased abun-dance of kielin/chordin, E3 ubiquitin ligase, and nucleophosmin 1 represented valuable fecal biomarkers indicating disease-related changes in the liver. Whereas a single biomarker failed to separate NASH and HCC, machine learning-based classification algorithms provided 0.86% accuracy in distinguishing between controls, NASH, and HCC. Conclusion: Fecal metaproteomics enables early detection of NASH and HCC by providing single biomarkers and ma-chine learning-based metaprotein panels.

2022-10-13 | PXD034175 | Pride

Altered fecal small RNA profiles in colorectal cancer reflect gut microbiome composition in stool samples

Project description:Dysbiotic configurations of the human gut microbiota have been linked with colorectal cancer (CRC). Human small non-coding RNAs are also implicated in CRC and recent findings suggest that their release in the gut lumen contributes to shape the gut microbiota. Bacterial small RNAs (bsRNAs) may also play a role in carcinogenesis but their role is less explored. Here, we performed small RNA and shotgun sequencing on 80 stool specimens of patients with CRC, or adenomas, and healthy subjects collected in a cross-sectional study to evaluate their combined use as a predictive tool for disease detection. We reported a considerable overlap and correlation between metagenomic and bsRNA quantitative taxonomic profiles obtained from the two approaches. Furthermore, we identified a combined predictive signature composed by 32 features from human and microbial small RNAs and DNA-based microbiome able to accurately classify CRC from healthy and adenoma samples (AUC= 0.87). In summary we reported evidence that host-microbiome dysbiosis in CRC can be observed also by altered small RNA stool profiles. Integrated analyses of the microbiome and small RNAs in the human stool may provide insights for designing more accurate tools for diagnostic purposes.

2019-08-30 | GSE132236 | GEO

Invasive pathobionts in intestinal microbiome contributes to cancer initiation by counterbalancing epithelial antimicrobial responses B

Project description:Microbiota dysbiosis and mucosa-associated bacteria are involved in colorectal cancer progression. We hypothesized that a time-specific interaction between dysbiotic pathobionts and host responses promote tumor growth. This study aimed to elucidate the dysfunctional host-microbe interplay in colon tumorigenesis by using a time-series metagenomics approach. A transient surge in fecal microbial richness was linked to a unique transcriptome profile in the mouse colon during carcinoma transformation. Monitoring gut microbiome may help identifying the window-of-opportunity to induce tumor regression using bacteria-targeted precision medicine.

2021-11-24 | GSE166038 | GEO

Invasive pathobionts in intestinal microbiome contributes to cancer initiation by counterbalancing epithelial antimicrobial responses A

2021-11-24 | GSE166030 | GEO

GNPS_Nobel_twin_study

Project description:Fecal samples from twins cohort (NOBEL study) to identify non-invasive biomarkers of disease severity in NAFLD.

2018-05-18 | MSV000082374 | GNPS